Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc. (NASDAQ: ORGS) is a pioneering biotech company focused on unlocking the potential of cell and gene therapies (CGTs). Headquartered in White Plains, New York, Orgenesis specializes in autologous therapies, employing a closed and automated processing system designed for compliant production close to the patient, enhancing the efficiency of treatments at the point of care (POCare).
The company operates through two main segments: Octomera and Therapies. Octomera is the company's decentralized cell therapy platform, which has been fundamental in their approach to CGT production. Their decentralized model allows for the integration of academia, hospitals, and industry partners to expedite the commercialization of these therapies. This approach not only reduces costs but also improves patient outcomes by bringing processing services closer to the patient.
Despite industry challenges in 2023, Orgenesis remains steadfast in its mission. CEO Vered Caplan highlighted the growing demand for decentralized cell therapy solutions due to cost pressures and patient demand. Orgenesis has seen support from regulators like the FDA and EMEA, who are progressing guidelines for decentralized production. These advancements have solidified the company’s strategic advantage in handling the development and regulatory processes of their products.
On the financial front, Orgenesis has made significant strides. The recent appointment of Victor Miller as CFO has brought renewed focus on their financial strategy, leveraging their robust cell processing expertise to secure their position in the life sciences sector. Their collaboration with Metalmark has provided critical support, aiding in navigating the biotech industry's fluctuations.
Orgenesis is also at the forefront of developing therapeutic exosomes through their EXOFASTTRACK project. This project aims to accelerate the clinical evaluation of therapeutic exosomes, providing a scalable and cost-effective production process that can revolutionize the field of advanced therapy medicinal products (ATMPs).
Furthermore, Orgenesis has strengthened its infrastructure through a strategic partnership with Germfree. This collaboration focuses on advancing Orgenesis’ therapeutic programs and cell processing services, aiming to make CGTs more accessible and affordable globally. The partnership also includes marketing Orgenesis' decentralized Octomera service platform and its Mobile Processing Units and Labs (OMPULs™).
Orgenesis continues to innovate and expand its global footprint, committed to bringing life-saving therapies to market faster and more efficiently. Their decentralized approach and strategic collaborations position them as leaders in transforming how cell and gene therapies are developed and delivered.
For more information, please visit www.orgenesis.com.
Orgenesis Inc. (NASDAQ: ORGS) announced its participation in the Winter Wonderland Conference hosted by The MicroCap Rodeo from February 16-19, 2021. CEO Vered Caplan is scheduled to present on February 16 at 2:30 PM Eastern Time, with a live webcast available. The conference features top investment ideas with one-on-one meetings for institutional investors on February 18-19. Orgenesis focuses on developing affordable cell and gene therapies through its POCare Platform, enabling scalable production at the point of care.
Orgenesis (NASDAQ: ORGS) reports a significant 40% revenue increase to $1.7 million in Q3 2020, up from $1.2 million in Q3 2019. Cash and cash equivalents stand at approximately $88.8 million as of September 30, 2020. The company continues to enhance its POCare strategy, expanding its therapeutic pipeline through the acquisition of Koligo Therapeutics. Upcoming projects include clinical trials for KT-PC-301, targeting COVID-19-related Acute Respiratory Distress Syndrome, and KYSLECEL, available for pancreatitis. Orgenesis also plans to roll out new automated cell therapy processing units globally.
Orgenesis (NASDAQ: ORGS) has announced that its 2020 Annual Meeting will be held virtually on November 18, 2020, due to the public health impact of COVID-19. Stockholders of record as of September 21, 2020, can attend the meeting via a provided link and control number. Pre-voting is encouraged, and proxy materials will not be updated to reflect the virtual format. Digital copies of the proxy statement and 2019 Annual Report are available on the company's website. This decision aims to prioritize stockholder health and well-being amidst ongoing pandemic challenges.
Orgenesis Inc (NASDAQ: ORGS) announced the completion of its acquisition of Koligo Therapeutics, Inc. and substantially all assets of Tissue Genesis, LLC, enhancing its POCare technology resources. The Icellator®, a point-of-care device for cell isolation, is now commercially available in Korea and the Bahamas, with plans for expansion into Japan by Q1 2021. The company aims to leverage these assets for developing affordable autologous cell therapies. The Koligo acquisition was valued at approximately $14.5 million in shares and included liabilities of $1.9 million.
Orgenesis Inc. (NASDAQ: ORGS) has signed a Services Agreement with Therapeutics, Inc. to develop its Ranpirnase topical formulation aimed at treating external genital warts caused by HPV. This collaboration precedes an investigational new drug submission and will explore enhanced targeting using Orgenesis’ Bioxomes™ technology. A Phase 2 study is planned for early 2021, building on promising Phase 1/2 results where Ranpirnase demonstrated safety and efficacy. EGW represents a significant health concern with around 400,000 new cases annually in the U.S.
Orgenesis Inc (NASDAQ: ORGS) provided a business update for Q2 2020, reporting a 55% revenue increase to $1.7 million from $1.1 million in Q2 2019. As of June 30, 2020, the company has $97.5 million in cash. Key advancements include collaborations for validating POCare Technologies and the launch of the BioShield Program to tackle viral pathogens like COVID-19. Orgenesis is advancing its cell-based vaccine platform and engaging in partnerships for treatments related to COVID-19, showcasing its commitment to innovative therapies at the point of care.
Orgenesis (NASDAQ: ORGS) has launched its BioShield Program aimed at accelerating the discovery and validation of neutralizing antibodies to combat viral outbreaks like COVID-19. The program will utilize its POCare anti-viral technologies to enhance immune response in animal models and could facilitate rapid identification of human neutralizing antibodies for antiviral therapies. Orgenesis is collaborating with partners from the Belgian biotech sector, including UCLouvain, to develop this initiative and improve preparedness against future pandemics.
Orgenesis Inc. (NASDAQ: ORGS) has entered into a Clinical Study Agreement with The Edith Wolfson Medical Center in Israel to conduct a clinical trial focused on validating its proprietary POCare Technologies. These technologies aim to improve the generation and expansion of tumor infiltrating lymphocytes (TIL) for cancer therapies. The automated cell culturing system is designed to simplify and optimize this process, potentially lowering manufacturing costs. Both parties expect this collaboration to advance cell and gene therapy products, providing high-quality solutions for cancer patients worldwide.
Orgenesis (NASDAQ: ORGS) has formed a research collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain, to establish a point-of-care center using its POCare Platform. This partnership aims to optimize and manufacture cell and gene therapies utilizing Orgenesis' proprietary technologies. The initial focus will be on developing T-cell and dendritic cell-based therapies, with plans to advance oncolytic cell therapy, Celyvir, for treating solid metastatic tumors. Both parties aim to reduce costs and improve the quality of therapy delivery.
Orgenesis Inc. (NASDAQ: ORGS) announced a stock repurchase plan, allowing up to $10 million in common stock buybacks. The plan begins on May 29, 2020, and will be funded from the company's working capital, which was approximately $107 million as of March 31, 2020. This buyback reflects management's belief that the current share price does not represent the company's true value. CEO Vered Caplan highlighted the positive impact of the recent sale of Masthercell, which generated around $127 million, bolstering the company's balance sheet and growth prospects in cell and gene therapies.
FAQ
What is the current stock price of Orgenesis (ORGS)?
What is the market cap of Orgenesis (ORGS)?
What is Orgenesis Inc.'s primary focus?
Where is Orgenesis Inc. headquartered?
What are the main business segments of Orgenesis Inc.?
What is the Octomera platform?
Who is the CEO of Orgenesis Inc.?
What strategic partnership did Orgenesis recently announce?
How does Orgenesis contribute to the development of therapeutic exosomes?
What is the significance of Orgenesis' decentralized approach?
How has Orgenesis addressed the challenges in the biotech industry?
Where can I find more information about Orgenesis?
